N/A N=26 Bladder ARFI (Acoustic Radiation Force Impulse) Study
Bladder Fibrosis
Primary: Shear Wave Velocity, VTQ — 1.95 meters per second
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=82 The Bladder Instillation Comparison Study
Urinary Bladder Neoplasms
Primary: Number of Participants Without Grade ≥ 3 Adverse Event, Graded According to NCI CTCAE Version 4.03 — 15; 14; 20 Participants
N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Phase 3 N=194 Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
Renal Interstitial Fibrosis
Primary: Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population — 26; 31; 12; 16 Participants
Phase 2 N=15 Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Bladder Cancer
Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants
N/A N=84 Treatment for Acute Postoperative Voiding Dysfunction
Urinary Retention
Primary: Persistent Retention — 29; 21 participants
N/A N=174 Recovery Support for Bladder Cancer Patients and Caregivers
Bladder Cancer · Patient Engagement · Patient Empowerment
Primary: Quality of Life Patient: The Functional Assessment of Cancer Therapy-Bladder Cancer-Cystectomy — 117.59; 118.70 Quality of Life Score — p=0.772
Phase 1 N=13 Colonizing Neurogenic Bladders With Benign Flora
Spinal Cord Injury · Urinary Tract Infection
Primary: Bladder Colonization — 62 percentage of participants
N/A N=16 Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
Interstitial Cystitis · Pelvic Pain
Primary: Change in Symptom Severity at 4 and 8 Weeks Post-Treatment as Measured by the Total O'Leary-Sant IC Symptom and Problem Index (ICSI/ICPI) Score — -4; -4 units on a scale
Phase 4 N=20 Botox as a Treatment for Interstitial Cystitis in Women
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Chronic Prostatitis Symptom Index (CPSI-F) — 29.6; 35.2 Total CPSI-F
Phase 3 N=133 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG
Bladder Cancer
Primary: Complete Response Rate at 3 Months — 39 percentage of participants
N/A N=30 Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder
Urinary Bladder, Neurogenic
Primary: Patient Perception of Bladder Condition Questionnaire — 3; 3 units on a scale
Phase 2 N=43 BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
Muscle Invasive Bladder Cancer
Primary: Pathologic Response Rate (PaR) at Time of Radical Cystectomy. PaR is Defined as Absence of Residual MIBC at Cystectomy in the Surgical Specimen (Pathologic Down-staging…
N/A N=44 Effects of Ketamine on Human Bladders and Its Possible Mechanisms
Cystitis
Primary: Substance Abuse Situation Record — 2 years
Phase 4 N=108 Neuromuscular Blockade During Transurethral Resection of Bladder Cancer
Neuromuscular Blockade
Primary: Number of Participants Attaining a 5 (Optimal) Surgical Condition Score — 16; 38 Participants
N/A N=20 Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis · Mindfulness · Complementary Medicine
Primary: Global Response Assessment (GRA) — 2; 0; 1; 3 participants
Phase 2 N=43 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
N/A N=27 The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides
Overactive Bladder
Primary: Change in the Relative Abundance of Lactobacillus — 0.143 proportion of total microbes
N/A N=214 Cystoinflation to Prevent Bladder Injury in Obstetrics and Gynaecology Surgery
Bladder Injury · Complications; Cesarean Section · Adhesions Pelvic
Primary: Bladder Injury Rate — 3; 22 Participants — p=<.0001
N/A N=130 Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
Muscle Invasive Bladder Cancer
Primary: Accuracy of the PET CT for Lymph Node Staging in Terms of Sensitivy Rate — 21 Participants
Phase 3 N=90 Clinical Trial Comparing Two Bladder Instillations for IC/BPS
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire — -6.7; -5.8 scores on a scale
N/A N=551 Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
Bladder Cancer
Primary: Recurrence Free Survival — 9.6; 16.4 months — p=0.056
N/A N=965 Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer
Bladder Cancer
Primary: Number of Participants With Recurrence and Recurrence Rate at 1 Year Following Narrow Band Imaging and TURB (Arm A) Versus White Light Trans Urethral Resection of…
N/A N=78 Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Chronic Interstitial Cystitis · Bladder Pain Syndrome · Cystitis, Interstitial
Primary: Change in the Genitourinary Pain Index (GUPI) 2 Months — 6.6; 4.8 score on a scale
Phase 4 N=120 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
Multiple Sclerosis · Urinary Bladder Diseases
Primary: Change From Baseline in the King's Health Questionnaire (KHQ) Domain Scores — 39.7; 2.5; 60.7; 1.2 Scores on a Scale
N/A N=10 PEMF Therapy to Treat Interstitial Cystitis/Bladder Pain Syndrome
Interstitial Cystitis · Chronic Interstitial Cystitis · Bladder Pain Syndrome
Primary: Pelvic Pain, as Measured by the Numeric Rating Scale (NRS) — 6.70 score on a scale
Phase 2 N=37 Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Bladder Cancer
Primary: Percentage of Participants Free From Radical Cystectomy at 3 Years — 88.2 percentage of participants
N/A N=40 Recovery of Bladder and Sexual Function After Spinal Cord Injury
Spinal Cord Injuries
Primary: Bladder Storage — 278.5; 447.75; 580.5; 313.0 mLH2O
Phase 2 N=29 Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Bladder Cancer
Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients
Phase 4 N=547 Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
Detrusor Overactivity · Overactive Bladder
Primary: Change From Baseline to Week 12 in Bladder Wall Thickness — 0.00; -0.29; -0.18; -0.24 mm — p=0.095